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Abstract
Background—Small studies have suggested differences in demographics and outcomes between 
left and right-sided deep vein thrombosis (DVT), and also unilateral vs. bilateral DVT. We 
investigated the clinical presentation and outcomes of patients with DVT based on thrombus 
sidedness.
Methods—We used the data from the Registro Informatizado Enfermedad TromboEmbólica 
(RIETE) database (2001-2016) to identify patients with symptomatic proximal lower-extremity 
DVT. Main outcomes included cumulative 90-day symptomatic pulmonary embolism (PE) and 1-
year mortality.
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Results—Overall, 30,445 patients were included. The majority of DVTs occurred in the left leg 
(16,421 left-sided, 12,643 right-sided, and 1,390 bilateral; P<0.001 for Chi-squared test comparing 
all 3 groups). Co-morbidities were relatively similar in those with left-sided and right-sided DVT. 
Compared with those with left-sided DVT, patients with right-sided DVT had higher relative 
frequency of PE (26% vs. 23%, P<0.001) and 1-year mortality (odds ratio [OR]: 1.08; 95% 
confidence interval [CI]: 1.00-1.18). This difference in mortality did not persist after multivariable 
adjustment (OR: 1.01; 95% CI: 0.93-1.1). Patients with bilateral DVT had a greater burden of co-
morbidities such as heart failure, and recent surgery compared with those with unilateral DVT 
(P<0.001), and higher relative frequency of PE (48%), and 1-year mortality (24.1%). Worse 
outcomes in patients with bilateral DVT were attenuated but persisted after multivariable 
adjustment for demographics and risk factors (OR: 1.64; 95% CI: 1.43-1.87). Patients with 
bilateral DVT had worse outcomes during and after discontinuation of anticoagulation.
Conclusions—There is a left-sided preponderance for proximal lower-extremity DVT. 
Compared with those with left-sided DVT, patients with right-sided DVT have slightly higher rates 
of PE. Bilateral DVT is associated with markedly worse short-term and 1-year outcomes.
Keywords
Deep vein thrombosis; right; left; bilateral; pulmonary embolism
Introduction
Thrombosis is the leading global cause of death.1 Venous thromboembolic disease (VTE) –
including deep vein thrombosis (DVT) and its potentially fatal consequence, pulmonary 
embolism (PE) – is one of the major thrombotic diseases, occurring in almost 1 million new 
cases annually, and remains a major health problem with high prevalence, incidence, 
mortality, morbidity, and costs.2–4
Much investigation has been done on various aspects of DVT epidemiology, including 
clinical presentation, natural history, and factors indicating a higher risk for PE, such as 
thrombus location (proximal or distal),5 co-morbidities,5 residual edema,6 and others. 
However, besides reports of more frequent occurrence of left-sided DVT in some prior 
studies,7–9 the significance of thrombus sidedness (right-sided, left-sided or bilateral DVT) 
has been largely under-studied. A prior investigation in a small cohort of patients for the first 
time suggested differences in underlying factors, as well as clinical outcomes of patients 
with right-sided lower limb DVT compared with those who had left-sided DVT, including 
increased risk of PE in patients with right-sided DVT.9 However, results of that small 
hypothesis-generating study have not yet been tested in a large patient population. Some 
studies have also suggested stronger association with cancer,10 and unfavorable outcomes 
such as subsequent PE or development of cancer in patients with bilateral DVT.9,11 
However, such findings have not yet been verified in a large cohort of patients. We used the 
Registro Informatizado Enfermedad Tromboembólica (RIETE) registry to validate the 
presence and significance of differences in presentation and prognosis of left-sided, right-
sided, and bilateral DVT in the lower limbs.
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Data Source and Study Protocol
We used the data from RIETE, the largest existing prospective registry of patients with 
objectively-confirmed VTE. Details about methodology of RIETE have been detailed 
elsewhere (ClinicalTrials.gov identifier: NCT02832245).12,13 In brief, RIETE is a 
multicenter registry of patients with diagnosed acute VTE. Initially started in Spain, RIETE 
currently has over 205 collaborating centers from 24 countries. The protocol for enrolling 
patients at RIETE for research purposes has been approved by the ethics committees at the 
participating sites. The study protocol for this manuscript was drafted by two authors (BB 
and MM) and reviewed by all coauthors.
Patients
For this study, we included patients with confirmed symptomatic proximal lower-extremity 
DVT who had available information about thrombus sidedness (i.e. left-sided, right-sided, or 
bilateral). By design, every effort is made in RIETE to include consecutive patients at 
participating centers. We excluded patients with isolated distal DVT (below knee), patients 
with upper extremity DVT, and patients with isolated PE (either diagnosed PE and negative 
work-up for DVT, or diagnosed PE and no available work-up for DVT). All patients 
provided verbal and or written informed consent for participation in RIETE, in accordance 
with local ethics committee requirements.
Outcomes
We reported, according to thrombus sidedness, the relative frequency of DVT, co-
morbidities, and major presenting symptoms and signs. The main outcomes of interest were 
the rate of cumulative 90-day symptomatic PE and its sub-components; concomitant PE at 
presentation with incident DVT event (i.e. PE diagnosed immediately before, along with, or 
immediately after DVT diagnosis), recurrent 90-day PE, and all-cause 1-year mortality rates. 
We also determined the rates of events during the course of anticoagulation, and after 
discontinuation of anticoagulation.
Statistical Analysis
We reported frequencies for categorical variables and mean with standard deviation for 
quantitative variables. We compared the frequencies of categorical variables using the Chi-
square test across the three groups. We used Kaplan-Meier curves to present 1-year mortality 
rates in patients with left-sided, right-sided, and bilateral DVT. We used logistic regression 
analysis to determine whether thrombus sidedness (left-sided vs. right-sided) is a predictor 
of 1-year mortality, and if so, whether the association persists after adjustment for 
demographics and clinical risk factors. We used patients with left-sided DVT as the referent. 
We used a separate multivariable model to determine whether bilateral DVT (vs. unilateral 
DVT) is a predictor of 1-year mortality. We reported 1-year rates of new diagnosis of cancer 
based on thrombus sidedness in patients with new DVT and no prior diagnosis of cancer. To 
report the results during versus after use of anticoagulation, we reported the rate of adverse 
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events per 100 patient-years. All analyses were performed by SPSS (version 20, SPSS Inc. 
Chicago, IL).
Results
From January 2001 to September 2016, a total of 42,356 valid patients with DVT were 
enrolled in RIETE. After exclusions of those with upper extremity DVT or unclear 
information about thrombus sidedness (5,272), or isolated distal lower extremity DVT 
(6,639), a total of 30,445 patients entered the study (Figure 1). Among 30,445 with 
symptomatic proximal lower-extremity DVT, the majority were in the left lower extremity: 
16,421 (53.9%) were left-sided, 12,634 (41.5%) were right-sided, and 1,390 (4.6%) were 
bilateral (P<0.001). Relative frequency of female gender was higher for left-sided DVT 
(51% vs. 45%, P<0.001). In patients with left-sided DVT versus right-sided DVT, co-
morbidities were relatively similar, except for a difference in frequency of underlying 
malignancy (21% vs. 23%, P<0.001). Patients with bilateral DVT had an overall greater 
burden of co-morbidities and risk factors, including heart failure, prior myocardial 
infarction, recent surgery, or immobility compared with those with unilateral DVT. Co-
existing cancer was reported in 40% of patients with bilateral DVT. Although use of 
anticoagulants was similar in the three groups, patients with bilateral DVT more frequently 
received thrombolytic therapy or inferior vena cava filters (P<0.001 for both comparisons, 
Table 1).
Rates of PE
Compared with patients with left-sided DVT, those with right-sided DVT more frequently 
had concomitant PE; while patients with bilateral DVT had markedly higher rates of 
concomitant PE than the two former groups (P<0.001 for all comparisons, Table 2). 
Similarly, compared with patients with left-sided DVT, the rate of subsequent 90-day new 
PE was higher in those with right-sided DVT, although the difference did not reach 
statistical significance (P=0.07). Patients with bilateral DVT had a significantly higher rate 
of subsequent new PE compared with those with unilateral DVT (P<0.001). Cumulative 
rates of 90-day symptomatic PE in those with left-sided, right-sided, and bilateral DVT were 
23%, 26%, and 48% (P<0.001 for all comparisons).
Mortality Rates
In patients with left-sided, right-sided, and bilateral DVT, 30-day mortality rates were 2.9% 
(0.30% fatal PE), 3.3% (0.43% fatal PE), and 9.4% (1.2% fatal PE), respectively. At 90-day 
follow-up, corresponding rates were 5.8%, 6.3%, and 15.7%. At 1-year follow-up, 
cumulative mortality rates in the three groups were 10%, 10.7%, and 24.1% (Figure 2). 
Compared with patients with left-sided DVT, patients with right-sided DVT had a higher 1-
year mortality rate (odds ratio [OR]: 1.08; 95% confidence interval [CI]: 1.00-1.18). 
However, the difference did not persist after multivariable adjustment (OR: 1.01; 95% CI: 
0.93-1.1). Patients with bilateral DVT had a markedly higher risk of 1-year mortality (OR: 
2.50; 95% CI: 2.19-2.86). By multivariable adjustment the association was partially 
attenuated but persisted (OR: 1.64; 95% CI: 1.43-1.87).
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Major bleeding events (requiring transfusion ≥2 units of blood, or being retroperitoneal, 
spinal or intracranial, or fatal) during the first 30 days occurred in 213 (1.3%), 167 (1.3%), 
and 38 (2.7%) of patients with left-sided, right-sided, and bilateral DVT, respectively. The 
rates of non-major bleeding were comparable between the three groups (1.4%, 1.3%, and 
1.5%).
Subsequent Cancer
There were no differences in 30-day or 1-year subsequent diagnosis of cancer in those with 
left-sided, right-sided, and bilateral DVT (Table 2).
Outcomes During versus After Completion of Anticoagulant Therapy
In analyses performed per 100-person years of each subgroup, rates of thrombotic events, 
hemorrhagic events, and mortality were consistently higher in those with bilateral DVT 
during the course of anticoagulation, as well as after cessation of anticoagulant therapy 
(Table 3).
Discussion
Our study showed higher relative frequency of left-sided DVT, but significantly higher rates 
of cumulative symptomatic 90-day PE and 1-year mortality in those with right-sided DVT 
compared with left-sided DVT, although the magnitude of the differences were small and the 
mortality difference was not present in adjusted analyses. More importantly, we 
demonstrated that bilateral DVT compared with unilateral DVT, frequently occurs in 
patients with a greater burden of co-morbidities, and is associated with higher rates of PE, 
short-term mortality and 1-year mortality. The difference in outcomes of those with bilateral 
versus unilateral DVT attenuated but persisted after multivariable adjustment for 
demographics, risk factors, and co-morbidities. Results were consistent across multiple 
analyses in short-term or longer term, and over the course of anticoagulation, as well as after 
cessation of anticoagulant therapy.
There are multiple potential explanations for the observed worse outcomes with bilateral 
DVT compared with unilateral DVT. Patients with bilateral DVT had a higher co-morbidity 
burden and their DVT might function as a risk marker, supported by our multivariable 
models which demonstrated an attenuation of the strength of effect for bilateral DVT. 
However, the association persisted and as such, it could be hypothesized that bilateral DVT 
is indicative of a higher thrombotic burden and thereby greater likelihood of subsequent PE 
events, which could be fatal. Further, we noted a higher risk of PE-related death in patients 
with bilateral DVT. Worse outcomes in patients with bilateral DVT have been also suggested 
in some prior investigations.14 More frequent use of advanced therapies (such as 
thrombolytic therapy and also inferior vena cava filter placement) in our study among 
patients with bilateral DVT, are likely indicative of greater risk in those patients. To our 
knowledge, no prior comparative effectiveness study has evaluated distinct interventions, 
including more potent and or more prolonged antithrombotic therapy for bilateral DVT 
compared with unilateral DVT. Our findings suggest a potential need of such comparisons.
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In our study, we did not find a significant difference in the rate of subsequent cancer 
diagnosis based on thrombus sidedness among those who had unprovoked DVT. 
Interestingly, a recent investigation also showed that occult cancer diagnosis is infrequent in 
patients with a first unprovoked DVT.15 A prior RIETE investigation suggested bilateral 
DVT as a significant predictor of hidden cancer.16 However, a subsequent dedicated 
investigation showed that bilateral DVT was not an independent predictor of ensuing 
diagnosis of hidden cancer.17 Finally, we should reflect that in our study coexisting cancer 
was far more frequent in patients with bilateral DVT compared with unilateral DVT (40% 
vs. 22%).
Similar to prior investigations, we noted a higher relative frequency for left-sided DVT.
7–9,18–20 Prior studies reporting mortality had small number of patients. In the study by 
Bikdeli et al there was no significant difference in 3-month mortality rates between those 
with right-sided and left-sided DVT (P=0.25).9 The study by Lee et al did not clearly report 
the in-hospital mortality rates in the two groups.21 The study by Narayan et al did not report 
on mortality, either.22 The higher risk of PE observed in patients with right-sided DVT 
compared with left-sided DVT is consistent with prior studies in smaller cohorts.9,21,22 Such 
differences might be the result of a larger vein diameter, and more vertical orientation of 
right-sided lower extremity veins towards the inferior vena cava, making it more likely to 
cause PE.9 Further, in our study, we noted a higher relative frequency of left-sided DVT in 
women, and higher frequency of hormonal use or DVT in the setting of pregnancy/puerperal 
state in patients with left-sided DVT. While the absolute number of patients with such risk 
factors was small, younger age and lower co-morbidity burden of such patients may also 
play a role in the difference for outcomes of patients with left-sided and right-sided DVT. 
Such gender differences may also correlate with distinct anatomical abnormalities,23 which 
we were not able to investigate. Based on our results it would be prudent to be more wary of 
right-sided DVTs. Yet, we must acknowledge that such differences are not clinically large 
and would likely not require a distinct management strategy based on thrombus sidedness.
To our knowledge, this study is the largest investigation to compare the presentation and 
outcomes bases on thrombus sidedness. Our study has some limitations. First, RIETE, by 
design, does not follow central outcome adjudication. However, periodic audits for quality 
control of the registry have not shown major errors in reported outcomes by site 
investigators. In addition, certain outcomes are evaluated by the RIETE steering committee. 
Although we cannot exclude the possibility of some outcomes getting recoded by 
adjudication, such a limitation is unlikely to fundamentally impact our findings. Second, we 
did not have available details, beyond thrombus sidedness, to explore anatomical differences 
in patients with left-sided and right-sided DVT, including further exploration about the May-
Thurner syndrome. Third, our findings could not be extrapolated to those with asymptomatic 
or distal DVTs. RIETE, by design, does not ask the investigators to change the plan of care. 
For example, universal bilateral screening is not mandatory per RIETE for those with 
unilateral symptoms. As such, it is possible that for some of the patients with symptomatic 
right-sided or left-sided DVT, there was coexisting contralateral DVT that was undiagnosed 
by the site investigators. However, this limitation should have biased the results for 
comparison of outcomes between unilateral and bilateral DVT towards the null. Yet, we 
observed marked differences in outcomes. Our observed differences in outcomes of patients 
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with unilateral versus bilateral DVT might, in fact, underestimate the true differences. 
Finally, minimum required outcomes collection for RIETE extends to 3 months. Therefore, 
for 1-year analyses, inevitably, there were some dropouts. The consistent signal that we 
observed in various time intervals, however, confirms the robustness of our findings.
In conclusion, our study of a large cohort of patients showed preponderance of left-sided 
DVT, worse outcomes with right-sided DVT that attenuated in multivariable models, and 
also marked differences in co-morbidity burden and outcomes of patients with bilateral DVT 
versus unilateral DVT. Further studies are required to determine whether a specific 
management strategy could improve the outcomes for patients with bilateral DVT.
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Table 1
Basic Characteristics of Patients (N=30,445)
Left-sided DVT Right-sided DVT Bilateral DVT
Patients (%) 16,421 12,634 1,390
Demographics
Male (%) 8,020 (49%) 6,906 (55%)‡ 702 (51%)†
Age (years ± SD) 64.8±18.1 65.8±16.8‡ 65.9±17.3
Body mass index (kg/m2) 27.7±5.2 28±5.3‡ 26.9±5.2‡
Inpatient status 4,019 (25%) 3,126 (25%) 475 (35%)‡
Underlying conditions
Chronic lung disease 1,647 (10%) 1,318 (10%) 170 (12%)*
Chronic heart failure 777 (4.7%) 688 (5.4%)† 128 (9.2%)‡
Diabetes (N=16,982) 1,319 (14%) 1,115 (16%)† 154 (19%)*
Hypertension (N=17,042) 4,134 (45%) 3,275 (47%)* 402 (49%)
Prior myocardial infarction (N=16,973) 574 (6.3%) 460 (6.6%) 78 (9.5%)†
Prior ischemic stroke (N=16,962) 589 (6.4%) 447 (6.4%) 72 (8.8%)*
Recent major bleeding 306 (1.9%) 251 (2.0%) 56 (4.0%)‡
Anemia 5,650 (34%) 4,290 (34%) 691 (50%)‡
Abnormal platelet count 3,286 (20%) 2,593 (21%) 340 (24%)‡
Recent Surgery 1,490 (9.1%) 1,117 (8.8%) 175 (13%)‡
Recent immobility 3,917 (24%) 2,964 (23%) 399 (29%)‡
Active cancer 3,457 (21%) 2,882 (23%)‡ 556 (40%)‡
Prior VTE 2,726 (17%) 2,217 (18%)* 271 (19%)
Pregnancy/puerperium 381 (2.3%) 110 (0.87%)‡ 12 (0.86%)
Hormonal use 940 (5.7%) 554 (4.4%)‡ 46 (3.3%)
Initial therapy
Low-molecular-weight heparin 15,086 (92%) 11,525 (91%)* 1,147 (83%)‡
Unfractionated heparin 639 (3.9%) 556 (4.4%)* 150 (11%)‡
Fondaparinux 286 (1.7%) 216 (1.7%) 34 (2.4%)*
NOACs 218 (1.3%) 171 (1.4%) 17 (1.2%)
Thrombolytic therapy 104 (0.63%) 73 (0.58%) 26 (1.9%)‡
Vena cava filter 455 (2.8%) 329 (2.6%) 114 (8.2%)‡
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‡
P<0.001.
COPD: chronic obstructive lung disease, DVT: deep vein thrombosis, IU: international units, LMWH: low-molecular-weight heparin, NOACs: 
Non-vitamin K oral anticoagulants, PE: pulmonary embolism, SD: standard deviation, VTE: venous thromboembolism
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Table 2







Cumulative 90-day PEs 3,752 (23%) 3,252 (26%)‡ 672 (48%)‡
Concomitant symptomatic PE (%) 3,634 (22%) 3,137 (25%)‡ 648 (47%)‡
Subsequent symptomatic 90-day PE 118 (0.72%) 115 (0.91%) 24 (1.7%)†
Mortality
30-day all-cause mortality (%) 479 (2.9%) 417 (3.3%) 130 (9.4%)‡
30-day PE-specific mortality (%) 49 (0.30%) 54 (0.43%) 17 (1.2%)‡
Subsequent cancer in patients with unprovoked VTE 7,893 6,304 440
Day 90 73 (0.92%) 45 (0.71%) 5 (1.14%)
Day 365 134 (1.70%) 98 (1.55%) 6 (1.36%)
over Day 365 187 (2.37%) 145 (2.30%) 8 (1.82%)







DVT: deep vein thrombosis, PE: pulmonary embolism.
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